Back to search

Democritus University of Thrace (DUTH)

Αποτελεσματικότητα προπαρασκευαστικών σχημάτων ελαττώμενης ισχύος στην αλλογενή μεταμόσχευση αιμοποιητικών κυττάρων σε πάσχοντες από κακοήθεις αιματολογικές παθήσεις

Abstract

dc:description

Allogeneic hematopoietic stem cell transplantation (HCT) has become a curative therapy for hematological malignancies and a variety of non malignant disorders for forty years. High doses of chemotherapy and radiation, combined with a new immune system generated by an allogeneic graft, have significant potential benefits for the treatment of multiple types of disease. Evidence for the importance of the new immune system in impoving outcome for patients undergoing HCT continues to grow. The aggressive induction regimens utilized in standard HCT may result in multiple organ toxicity; furthermore, prolonged time to engraftment and prolonged use of immunosuppression results in increased risk for bacterial, viral and fungal infections. HCT with fully ablative conditioning is associated with an age - related increase in TRM. It is therefore contra-indicated for older individuals who are mainly at risk of developing other comorbitidies. Due to the high treatment related toxicity in allogeneic transplant and the advanced age of most patients, pioneer investigators have begun evaluating the use of reduced intensity regimen. As a potential solution to the problems of excessive regimen - related toxicity, the reduced intensity or non myeloablative allograft was introduced in the mid-1990s. Short term toxicity is generally decreased so the benefits of allogeneic HCT can potentially be extended to selected younger patients or patients suffering from certain diseases with an evident graft versus leukemia sensitivity in early disease stage. In addition to its utility in patients considered unsuitable for standard “classic” myeloablative HCT, reduced intensity allogeneic HCT RIST is increasingly being used as an alternative approach in patients who could otherwise be eligible for RIST and in a tandem autograft - allograft setting. Allogeneic hematopoietic stem cell transplantation (RIST) eradicates malignant cells through a graft-versus-malignancy leukemia effect (GVM-GVL) provided by alloreactive donor T lymphocytes. Various studies have clearly demonstrated the GVL-GVM effect in hematologic malignancies: 1) reduced incidence of leukemic relapse in non syngeneic HCT or in recipients developing GVHD or post Tcell repleted allografts 2) remission induction after DLI in patients relapsed after HCT. During the last ten years single center studies using reduced intensity conditioning followed by allogeneic HCT have been reported in adults. Two general strategies have emerged. One category is based upon immunosuppressive chemotherapeutic drugs usually a purine analog in combination with an alkylating agent. The other approach is based upon low dose total body irradiation. Reduced intensity conditioning regimens are heterogeneous with regard to dose of chemotherapy and radiotherapy and degree of immunosuppression. There are 2 types of conditioning: 1) truly non myeloablative which should allow hematopoietic recovery <28 days without a transplantation and mixed chimerism should be present upon engraftment; 2) reduced myelotoxicity regimens which require a transplant for hematologic recovery. Thirty-seven patients with a median age of 50 (15-63) were allografted from HLA- matched sibling (n: 35) or 8 of 8 allele- matched unrelated (n:2) donors after a reduced chemotherapy based intensity conditioning. They suffered from AML (11), ΜDS (2), ALL (1), NHL (6), Hodgkin disease (6), Mantle NHL (5), MM (2), CLL(3), CML (1). The median follow up was 16 (3-54) months. Fifteen patients had a high disease burden characterized by bulky disease or infiltration of marrow with blasts >10% and 26/37 advanced disease. Τhirteen patients had already undergone stem cell transplantation (11 autologous and 2 allogeneic) pre RIST transplantation. The reduced conditioning regimen was mainly FLUDARABIN-based combined with; busulfan+ATG (18), busulfan+mabCampath (1) busulfan+endoxan (1), endoxan (10) endoxan+ATG (1) endoxan+thiotepa (1) or melphalan (3), idarubicin+aracytin (1) busulfan (1). Thirty-five patients received mobilized peripheral blood graft and 2 patients marrow grafts. Αnti-GVHD prophylaxis mainly consisted of CsA+MMF. The median graft cell dose was: CD34+: 6 x106/kg, CD3+: 4,84 x108/kg. Thirty-five patients engrafted with a median time to reach neutrophils ? 500/μl +10 day and platelets ?50000 /μl +11 day after cytopenia of 8 (4-27) days. Six patients did not receive any red cell transfusion and 10 any platelet transfusion. Twenty-one patients did not develop mucositis and no parenteral nutrition was administered to 18 patients. Full chimerism was succeeded in 25 patients (76%) at a median day +60 (14-180). On multivariate analysis, full chimerism at day +30 was strongly related to: low tumor burden, CD3 cell dose above the median number >4,84 X 108/kg which was further related with the time to full chimerism.Thirteen patients developed aGVHD (35%), of which 9 had clinically significant (? grade II-IV) disease, was related with the non administration of ATG, specific IL2, IL1B recipient cytokine gene polymorphism and the achievement of full chimerism. Complete or partial remission was attained in 27/37 patients. On multivariate analysis, response was related to: low tumor burden at RIST, full chimerism even in the advanced disease. The probability of relapse at 51 months was 50% and was significantly related with: high tumor burden, preceding lines of therapy and ATG administration. Sixteen patients were treated with combined immunotherapeutic approaches; abrupt cessation of CsA, administration IL2 / IFΝ-a, donor lymphocyte infusions or cryo-preserved graft and 46% responded after developing GVHD. The probability Progression Free Survival (PFS) at 4,5 years was estimated to be 27%, higher (39%) for patients with low tumor burden and after full chimerism. On multivariate analysis, only the response to RIST was the strongest predictive factor for outcome. The 4,5-year overall survival was estimated to be 30%. It was higher in early vs. advanced disease (62% vs. 19%). In conclusion, RIST seems to be effective in patients with low tumor burden in early disease with low toxicity even in advanced age.

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2007

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Sakellari, Ioanna
  • Σακελλάρη, Ιωάννα

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/21133

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Sakellari, Ioanna; Σακελλάρη, Ιωάννα. Αποτελεσματικότητα προπαρασκευαστικών σχημάτων ελαττώμενης ισχύος στην αλλογενή μεταμόσχευση αιμοποιητικών κυττάρων σε πάσχοντες από κακοήθεις αιματολογικές παθήσεις. Democritus University of Thrace (DUTH), 2007. http://hdl.handle.net/10442/hedi/21133